These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1834144)

  • 1. The pharmacodynamics and pharmacokinetics of a novel thromboxane receptor blocking drug vapiprost (GR32191) after single intravenous doses in healthy subjects.
    Thomas M; Keery RJ; Charter MK; Scully NL; Chilton JE; Lumley P
    Br J Clin Pharmacol; 1991 Aug; 32(2):181-6. PubMed ID: 1834144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers.
    Uematsu T; Nagashima S; Mizuno A; Hirano K; Nakashima M
    J Clin Pharmacol; 1991 Sep; 31(9):815-22. PubMed ID: 1839540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary assessment of a novel thromboxane A2 receptor-blocking drug, GR32191, in healthy subjects.
    Thomas M; Lumley P
    Circulation; 1990 Jan; 81(1 Suppl):I53-8; discussion I59-60. PubMed ID: 2136818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
    Lumley P; White BP; Humphrey PP
    Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the mechanism of the prolonged action in man of GR32191, a thromboxane receptor antagonist.
    Ritter JM; Doktor HS; Benjamin N; Barrow SE; Stewart-Long P
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():351-4. PubMed ID: 1825568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
    Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M
    Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional vascular responses to thromboxane A2 analogue and their blockade with vapiprost, a selective thromboxane receptor blocking drug, in anesthetized dogs.
    Noguchi K; Ojiri Y; Chibana T; Matsuzaki T; Sakanashi M
    Jpn J Pharmacol; 1992 Dec; 60(4):341-8. PubMed ID: 1287269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a selective thromboxane receptor antagonist (GR32191B) and of glyceryl trinitrate on bleeding time in man.
    Ritter JM; Benjamin N; Doktor HS; Barrow SE; Mant TG; Schey S; Stewart-Long P
    Br J Clin Pharmacol; 1990 Apr; 29(4):431-6. PubMed ID: 2139338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of the binding of [3H]-GR32191 to the thromboxane (TP-) receptor of human platelets.
    Armstrong RA; Humphrey PP; Lumley P
    Br J Pharmacol; 1993 Oct; 110(2):539-47. PubMed ID: 8242228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the new thromboxane A2 antagonist vapiprost on isolated canine blood vessels.
    Matsuzaki T; Noguchi K; Nakasone J; Uezu K; Higuchi M; Sakanashi M
    Arzneimittelforschung; 1992 Nov; 42(11):1318-22. PubMed ID: 1492844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effect of vapiprost on contractile responses of isolated dog renal arteries to thromboxane A2 analogue, U46619.
    Sakanashi M; Matsuzaki T; Noguchi K; Nakasone J; Itomine T; Uza M; Toyama F; Higuchi M
    Gen Pharmacol; 1994 Jul; 25(4):617-22. PubMed ID: 7958719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.
    Matsuno H; Uematsu T; Umemura K; Takiguchi Y; Wada K; Nakashima M
    Br J Pharmacol; 1992 Jul; 106(3):533-8. PubMed ID: 1387025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of GR32191, R68070 and CV-4151 upon U-46619- and collagen-induced platelet aggregation in vitro and ex vivo.
    Watts IS; White BP; Wharton KA; Lumley P
    Br J Pharmacol; 1989 Dec; 98 Suppl():842P. PubMed ID: 2611538
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of age on the pharmacokinetics of vapiprost, a thromboxane A2 receptor antagonist, and platelet aggregation: comparison of pharmacokinetics by routine approach and population pharmacokinetics.
    Ohashi K; Aso R
    Int J Clin Pharmacol Res; 2001; 21(2):85-94. PubMed ID: 11824652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction.
    Beasley RC; Featherstone RL; Church MK; Rafferty P; Varley JG; Harris A; Robinson C; Holgate ST
    J Appl Physiol (1985); 1989 Apr; 66(4):1685-93. PubMed ID: 2525122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion.
    Hornby EJ; Foster MR; McCabe PJ; Stratton LE
    Thromb Haemost; 1989 Jun; 61(3):429-36. PubMed ID: 2529661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
    Guth BD; Müller TH
    Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A2-receptor antagonist AA-2414 in normal subjects: population analysis.
    Hussein Z; Samara E; Locke CS; Orchard MA; Ringham GL; Granneman GR
    Clin Pharmacol Ther; 1994 Apr; 55(4):441-50. PubMed ID: 8162671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers.
    Uematsu T; Kosuge K; Umemura K; Nakano M; Terakawa M; Nakashima M
    J Pharm Pharmacol; 1996 Apr; 48(4):380-5. PubMed ID: 8794987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.